Celcuity CEO Sets July 17 PDUFA for Gedatolisib, Teases VIKTORIA-1 Mutant Data at Conference
Celcuity (NASDAQ:CELC) CEO Brian Sullivan outlined the company’s expected regulatory timeline and commercial preparations for gedatolisib during an appearance at the Guggenheim Healthcare Conference, while also previewing upcoming clinical catalysts and how the company views the therapy’s positioning in breast cancer. Regulatory timeline and upcoming data Sullivan said the FDA has set a Prescription Drug […]
14 Feb 15:04 · The Markets Daily